Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Key Inclusion Criteria: * Urinary Incontinence for at least 3 months prior to Screening as a result of Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis. * Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or below which occurred at least 6 months prior to Screening. * Subjects with Multiple Sclerosis must be clinically stable in the investigator's opinion, with no exacerbation (relapse) of MS for at least 3 months prior to Screening. * Subjects must have had an inadequate response after at least 4 weeks of oral medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists) and/or have intolerable side-effects. * Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate bladder emptying. * An average of at least two episodes per day of Urinary Incontinence recorded on the screening bladder diary. Key Exclusion Criteria: * Any current condition (other than NDO) that may impact on bladder function. * Previous or current, tumour or malignancy affecting the spinal column or spinal cord, or any other unstable cause of SCI. * Any condition that will prevent cystoscopic treatment administration or CIC usage, e.g. urethral strictures. * Current indwelling bladder catheter, or removal of indwelling bladder catheter less than 4 weeks prior to Screening. * BTX-A treatment within 9 months prior to Screening for any urological condition (e.g. detrusor or urethral sphincter treatme…